AstraZeneca 2020 revenue rises, sales growth to take coronavirus hit
AstraZeneca said the guidance assumed an unfavourable impact from China lasting up to a few months as a result of the outbreak, which has killed over 1,300 people and is still spreading.
US: AstraZeneca expects 2020 revenue growth in the high single-digit to low double-digit percentages, including a hit it now expects from the coronavirus outbreak in China, its second-biggest market, the British drugmaker said on Friday.
The company said the guidance assumed an unfavourable impact from China lasting up to a few months as a result of the outbreak, which has killed over 1,300 people and is still spreading.
Read also: AstraZeneca Lokelma gets Chinese approval for treating hyperkalaemia
Product sales for the three months ended Dec. 31 rose 9% to $6.25 billion, on a constant-currency basis, marking the sixth consecutive quarter of growth after years of sliding sales due to patent losses on older medicines.
Read also: AstraZeneca to end heart drug Epanova trial, expects USD 100 million writedown
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd